We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Jogging in the Change of Osteoporosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03359317
Recruitment Status : Not yet recruiting
First Posted : December 1, 2017
Last Update Posted : December 1, 2017
Information provided by (Responsible Party):

November 26, 2017
December 1, 2017
December 1, 2017
February 20, 2018
January 30, 2019   (Final data collection date for primary outcome measure)
DEXA T-score [ Time Frame: 1 year ]
Bone mineral density change in spine, hip and femur after 1 year of jogging
Same as current
No Changes Posted
Number of fractures [ Time Frame: 1 year ]
Number of fractures occurring while in study
Same as current
Not Provided
Not Provided
Jogging in the Change of Osteoporosis
Jogging in the Change of Osteoporosis
To test the changes in osteoarthritis according to the X-rays, and changes in bone quality before and 1 or more years after beginning the jogging
Patients in this research are given an entry Bone Densitometry(DEXA)scan and are required to advance from 3-minute jogging a day to 10-minute level in daily practice for 1 year as instructed. After 1 year, subsequent DEXA scans are recorded. Interested participants are also encouraged to have hip and spine X-rays, and bone quality studies on study entry and two years later. Actual subject participation, intercurrent illnesses, fractures and changes in medication are self-monitored. Results are calculated by change in bone mineral density in the lumbar spine, hips and femurs by the DEXA scan in the study. Dose-response relationships between the amount of jogging and bone mineral density are sought. Jogging-related fractures and other adverse effects are also noted.
Not Provided
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Behavioral: jogging
Jogging as instructed for 1 year
Experimental: jogging
At least 5 times/week
Intervention: Behavioral: jogging
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Not yet recruiting
January 30, 2019
January 30, 2019   (Final data collection date for primary outcome measure)

Inclusion Criteria:

Past DEXA scan and, all within 6 months of study entry, DEXA scan and normal values for: Metabolic panel, TSH, PTH, ESR (or CRP), Vitamin D 25 hydroxy, Vitamin D 1,25 dihydroxy, Urine NTX

Exclusion Criteria:

Known metabolic bone disease such as osteogenesis imperfecta, current treatment with steroids, chemotherapy, or currently healing fractures of lumbar spine, hips or femurs, severe heart disease

Sexes Eligible for Study: All
50 Years to 60 Years   (Adult)
Contact: Peixun Zhang, MD 15210802766 875274428@qq.com
Not Provided
Not Provided
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Plan to Share IPD: No
Zhang Yichong, Peking University People's Hospital
Peking University People's Hospital
  • Shenzhen Sun Yat-sen Cardiovascular Hospital
  • Wujin People's Hospital
  • Chongqing Zhongshan Hospital
Principal Investigator: Peixun Zhang, MD Peking University People's Hospital
Peking University People's Hospital
November 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP